Decatur Capital Management Inc. cut its holdings in Becton Dickinson and Co (NYSE:BDX) by 13.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,544 shares of the medical instruments supplier’s stock after selling 3,528 shares during the period. Decatur Capital Management Inc.’s holdings in Becton Dickinson and were worth $4,826,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of BDX. Harvest Fund Management Co. Ltd increased its position in shares of Becton Dickinson and by 82.8% during the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after purchasing an additional 338 shares in the last quarter. Investec Asset Management LTD increased its position in shares of Becton Dickinson and by 14.5% during the second quarter. Investec Asset Management LTD now owns 455,628 shares of the medical instruments supplier’s stock worth $88,898,000 after purchasing an additional 57,736 shares in the last quarter. Acrospire Investment Management LLC increased its position in shares of Becton Dickinson and by 259.7% during the second quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock worth $162,000 after purchasing an additional 600 shares in the last quarter. BRYN MAWR TRUST Co increased its position in shares of Becton Dickinson and by 0.4% during the second quarter. BRYN MAWR TRUST Co now owns 152,696 shares of the medical instruments supplier’s stock worth $29,793,000 after purchasing an additional 584 shares in the last quarter. Finally, New York State Common Retirement Fund increased its position in shares of Becton Dickinson and by 25.3% during the second quarter. New York State Common Retirement Fund now owns 936,270 shares of the medical instruments supplier’s stock worth $182,676,000 after purchasing an additional 189,183 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

BDX has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Wells Fargo & Co reiterated a “positive” rating and set a $235.00 target price (up previously from $225.00) on shares of Becton Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Royal Bank of Canada reiterated a “hold” rating and set a $210.00 target price on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Morgan Stanley raised their price target on Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $245.00 price target on shares of Becton Dickinson and in a report on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $237.27.

Becton Dickinson and Co (NYSE:BDX) opened at $217.14 on Friday. The company has a current ratio of 1.54, a quick ratio of 5.03 and a debt-to-equity ratio of 1.04. Becton Dickinson and Co has a twelve month low of $175.66 and a twelve month high of $248.39. The stock has a market capitalization of $57,811.79, a PE ratio of 22.52, a P/E/G ratio of 1.49 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the previous year, the company earned $2.33 EPS. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. analysts expect that Becton Dickinson and Co will post 10.95 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be issued a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.38%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is presently 229.01%.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://theolympiareport.com/2018/02/11/decatur-capital-management-inc-has-4-83-million-holdings-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.